Biotech Showcase™ 2017: Unmet needs, uncommon commitment: The shift toward investment in rare diseas

January 17, 2017

Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candid, interactive and enlightening panel discussion about the evolving landscape in rare disease drug discovery and development. The panel discuss how approaches to rare disease research, drug development, commercialization and investment have changed in recent years, and why and how they’ve chosen to pursue leadership and innovation in rare diseases.

 


Alison Silva will be moderating a panel at BIO-Europe Spring in Barcelona this March 20-22, 2017 called "The business of rare disease company development" Learn more here 

Previous Article
Unmet needs, uncommon commitment: The shift toward investment in rare diseases
Unmet needs, uncommon commitment: The shift toward investment in rare diseases

Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interact...

Next Article
Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017
Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

As the intensity of Biotech Week in San Francisco winds down, join our exclusive panel of all-star reporter...